Join
Live feed
·
PRReleasevia Quantisnow
MEI Pharma Inc. logo

MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as a Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma

ByQuantisnow·Wall Street's wire, on your screen.
MEIP· MEI Pharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MEIP (MEI Pharma Inc.) and more on Quantisnow.